Moleculin Biotech Inc. (MBRX)
NASDAQ: MBRX
· Real-Time Price · USD
0.50
-0.03 (-5.66%)
At close: Oct 02, 2025, 3:59 PM
-5.66% (1D)
| Bid | 0.48 |
| Market Cap | 15.11M |
| Revenue (ttm) | 126K |
| Net Income (ttm) | -26.55M |
| EPS (ttm) | -3.74 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | -0.35 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.52 |
| Volume | 2,746,769 |
| Avg. Volume (20D) | 5,599,368 |
| Open | 0.53 |
| Previous Close | 0.53 |
| Day's Range | 0.48 - 0.53 |
| 52-Week Range | 0.25 - 3.65 |
| Beta | 1.50 |
| Ex-Dividend Date | n/a |
About MBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+11.33%
MBRX stock has given up its prior gain. Moleculin ...
Unlock content with
Pro Subscription
1 month ago
+11.33%
Moleculin Biotech shares are trading higher after the company announced the completion of its Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of subjects with acute myeloid leukemia
